Teva UK, a part of Teva Pharmaceutical Industries, has announced the launch of generic Irbesartan tablets.
Irbesartan, a generic version of Aprovel (Irbesartan) by Sanofi Pharma Bristol-Myers Squibb SNC, is indicated to treat essential hypertension and renal disease in patients with hypertension and type 2 diabetes mellitus as part of an antihypertensive medicinal product regimen.
Teva commercial director Kim Innes said the company has launched 22 products in 2012 including now eleven day-one patent expiries in a variety of strengths and pack sizes.
"It's good for Pharmacy because patent expiries provide them with the opportunities for increasing margins and keeping costs down. But, importantly, it also means that we continue to help save the NHS over 9bn a year," Innes added.
The company announced the availability of the Irbesartan tablets in the Teva 360 livery in 75mg, 150mg and 300mg dose strengths.
